Analgesic Effect of Resistance Training for Breast Cancer Survivors

Breast Cancer Clinical Trial

— (ANTRAC)  

Official title:

Effect of Resistance Training of Persistent Pain After Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04509284
• Other study ID #: N-20180090
• Secondary ID: R204-A12469
• Status: Completed
• Phase: N/A
• Start date: August 10, 2020
• Est. completion date: September 23, 2021

Study information

• Verified date: January 2022
• Source: Aalborg University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Persistent pain after treatment for breast cancer is a major clinical problem, affecting 25-60 % of the patients and is a source of considerable physical disability and psychological distress. Thus, the development of novel interventions to improve pain management for these patients is of clinical importance. Resistance training (RT) is a promising tool to combat a variety of undesirable adverse effects due to breast cancer treatment. Further, research suggests that it may also be able to provide pain-relieving benefits. Hypothesis: Resistance training will improve pain perception and physical function in the short- and long term compared to a non-training control group.

Description:

Breast cancer is the most common cancer in women worldwide with more than a million new cases diagnosed every year [1]. Fortunately, due to better treatment options, the population of long-term survivors is increasing. This poses new demands for knowledge on how to manage late effects to the treatment regimen. Persistent pain after treatment for breast cancer is a common and underestimated problem as well as it can be a source of considerable physical disability and psychological distress [2]. Hence, the development of novel interventions to improve pain management is of high clinical relevance. Resistance training (RT) is a promising clinical therapeutic tool to improve a variety of adverse effects to breast cancer treatment [3] and may provide several pain-relieving benefits [4]. However, the efficacy of this modality for managing persistent pain after breast cancer treatment is currently unclear. Therefore, the purpose of this project is to investigate if individualized RT can modulate persistent pain after breast cancer treatment, thereby improving our understanding of how this modality may benefit patients and contribute to clinical guidelines for pain management in this clinical population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 23, 2021
• Est. primary completion date: September 23, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• primary diagnosis of breast cancer (grades I-IIIA).
• adult women at least 18 years of age.
• having received breast cancer treatment (i.e. surgery and possible adjuvant chemo and/or radiotherapy) at least 18 months before the start of the study.
• self reported pain in the areas of the breast, shoulder, axilla, arm and/or side of body with an intensity of = 3 on a numeric rating scale (0 = no pain, 10 = worst pain imaginable).
• no signs of cancer recurrence.
• reading, writing and speaking Danish.

Exclusion Criteria:

• breast surgery for cosmetic reasons or prophylactic mastectomy.
• bilateral breast cancer.
• lymphedema.
• other chronic pain conditions (e.g., rheumatoid arthritis).
• previous diagnosis of fibromyalgia syndrome.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Chemotherapy Effect
• Chronic Pain
• Pain, Chronic
• Radiotherapy Side Effect
• Surgery

Intervention

Other:
• Training
The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
• Control
The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.

Locations

Country	Name	City	State
Denmark	Department of Health Science and Technology, Aalborg University	Aalborg	Northern Jutland

Sponsors (4)

Lead Sponsor	Collaborator
Aalborg University	Danish Cancer Society, Danish Cancer Survivor and Late Effects Group, Universidad de Granada

Country where clinical trial is conducted

Denmark, 

References & Publications (4)

Cronin-Fenton DP, Nørgaard M, Jacobsen J, Garne JP, Ewertz M, Lash TL, Sørensen HT. Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer. 2007 May 7;96(9):1462-8. Epub 2007 Apr 3. — View Citation

De Backer IC, Schep G, Backx FJ, Vreugdenhil G, Kuipers H. Resistance training in cancer survivors: a systematic review. Int J Sports Med. 2009 Oct;30(10):703-12. doi: 10.1055/s-0029-1225330. Epub 2009 Jul 7. Review. — View Citation

Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003 Jul;104(1-2):1-13. Review. — View Citation

Rice D, Nijs J, Kosek E, Wideman T, Hasenbring MI, Koltyn K, Graven-Nielsen T, Polli A. Exercise-Induced Hypoalgesia in Pain-Free and Chronic Pain Populations: State of the Art and Future Directions. J Pain. 2019 Nov;20(11):1249-1266. doi: 10.1016/j.jpain.2019.03.005. Epub 2019 Mar 21. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Summative process evaluation	The summative process evaluation include the following: 1) Context of the intervention described qualitatively, 2) the dose delivered as %'age of the planed sessions effectively implemented, 3) dose received as %'age of planned sessions effectively received, 4) fidelity measured through the following items: (1) whether the training groups (i.e. same participants every session) during training sessions were consistent; (2) whether the instructors delivered all their sessions as initially scheduled; (3) whether warm-up and training were offered in accordance with the time schedules initially planned; (4) whether the time schedule were respected by participants and instructors and 5) satisfaction, rated as level of agreement with a series of statements on a five-point likert scale 1=strongly disagree, 2=disagree, 3=uncertain, 4=agree, and 5=strongly agree.	At 3 months
Other	Training log, collecting daily readiness for exertion, performance, perceived exertion level and movement evoked pain.	Daily readiness for exertion is assessed at two levels (mental and physical) prior to the warm up and each exercise on a 0-11 numeric rating scale (0 = no readiness, 10 = maximum readiness. Performance i collected as setsXrepsXload per exercise per session. Perceived level of exertion is assessed through a resistance training specific Rating of Perceived Exertion (RPE) scale based on repetitions in reserve. Movement-evoked pain is assessed per set for each exercise on a 11 point numeric rating scale (0= no pain, 10 = maximum pain).	Every session for 12 weeks.
Primary	Change in pain sensitivity, assessed through pressure pain thresholds.	Between group comparisons of treatment effect (change in pressure pain thresholds) from baseline to follow-up) will be performed. Pressure pain thresholds will be collected with a pressure algometer with a progressive increment in pressure of 30kPa.	Baseline and at 3, and 6 months
Primary	Change in pain intensity, assessed through a 11 point numeric rating scale (0 = no pain, 10 = worst pain imaginable).	Pain intensity is collected in two different contexts; 1) recollection for the past 3 months and 2) movement evoked pain during testing and training.	Baseline and at 3, and 6 months
Secondary	Muscular strength assesses through a 1 repetition maximum (1RM)	1RM box squat, bench press, trapbar deadlift, bench pull and lat pulldown conducted in accordance with the recommendations of the American College of Sports Medicine (ACSM)	Baseline and at 3, and 6 months
Secondary	Active shoulder range of motion assessed with a universal goniometer.	Active range of motion for the affected shoulder is collected for shoulder flexion, horizontal shoulder flexion/extension, shoulder abduction and internal/external shoulder/rotation	Baseline and at 3, and 6 months
Secondary	Body composition assessed through bioelectrical impedance measurements.	Estimates of body fat mass, fat free mass, skeletal muscle mass and bodyfat percentage are collected from bioelectrical impedance using an InBody370 device.	Baseline and at 3, and 6 months
Secondary	Arm circumference measured bilaterally at a single point 30cm above the styloid process.	Arm circumference is collected to assess potential lymphedema development. A difference in circumference of >10% between arms is considered indicative of lymphedema.	Baseline and at 3, and 6 months
Secondary	Physical activity level assessed through the international physical activity questionnaire (IPAQ).	IPAQ estimates physical activity level as "low", "moderate" or "high" from the number of days and time per day conducting either hard, moderate or easy physical activity for the pas seven days.	Baseline and at 3, and 6 months
Secondary	Health related quality of life assessed through the European Organisation for Research and Treatment of Cancer (EORCT)-C30 quality of life questionaire	The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.	Baseline and at 3, and 6 months
Secondary	Quality of life assessed through the breast cancer specific European Organisation for Research and Treatment of Cancer (EORCT)-BR23 quality of life questionaire	The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in breast cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.	Baseline and at 3, and 6 months
Secondary	Cancer fatigue assessed through the Functional Assessment of Chronic Illness Therapy (FACIT) - fatigue scale.	The FACIT-scale estimates fatigue through a series of questions regarding the extent to which the respondee experience various symptoms of fatigue, ranging from 0 (not at all) to 4 (A lot) on a five point likert scale.	Baseline and at 3, and 6 months
Secondary	Mental health assessed through the Major Depression Index (MDI)	The MDI estimates mental health through a series of questions regarding the extent to which the respondee experience various symptoms of depression, ranging from 0 (never) to 5 (All the time) on a five point likert scale.	Baseline and at 3, and 6 months